HIV drug resistance in people on dolutegravir-based HIV therapy across many countries
Official title: HIV-1 subtype-specific drug resistance in patients failing Dolutegravir-based 1st, 2nd or 3rd line regimens: the International epidemiological Databases to Evaluate AIDS (IeDEA)
Funded at University of Zurich · NIH-11328206 · Data updated 2026-11-12
This grant studies how HIV may become resistant to dolutegravir-based treatment in people who are not responding well to therapy, across many countries and groups including children.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Zurich NIH-funded |
| Lab location | 1 site (Zurich, Switzerland) |
| Project start | September 1, 2021 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $717,966 |
| NIH project number | 2R01AI152772-05A1 |
| Project ID | NIH-11328206 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV who have virologic failure or low-level viremia while on dolutegravir-based ART, including infants and children.
✕Less likely to help
Patients who are fully suppressed on dolutegravir with no resistance signs may not directly benefit from additional testing.
What this research studies
If you are living with HIV and on dolutegravir-based regimens, this study looks at how resistance to the medication develops over time in routine care settings. Researchers will follow about 1,500 people from multiple sites across 11 countries to understand long-term resistance patterns and the clinical impact. The project will also expand to include infants and children to see how resistance evolves in younger patients and those with low levels of the virus in the blood. The goal is to inform better treatment choices and prevent treatment failure in real-world settings.
Why it matters
Potential benefit: Findings could guide more effective HIV treatment strategies and reduce the risk of treatment failure for people on dolutegravir.
How similar studies have gone: Previous DTG RESIST work showed resistance patterns; this renewal aims to clarify long-term evolution and clinical impact, building on prior findings.
Where this research is happening
-
University of Zurich
Zurich, Switzerland Active
Researchers
- Principal investigator: Kouyos, Roger Dimitri — University of Zurich
- Study coordinator: Kouyos, Roger Dimitri
Related research
Other NIH-funded projects on the same topics.
-
An integrated mobile health program to reduce SAVA and mental health problems among female sex workers in Kenya
A new mobile health program aims to help female sex workers in Kenya avoid substance abuse, violence, HIV, and depression by delivering group therapy, online resources, and a peer discussion space.
-
New thin, flexible tactile displays to make screens accessible for people who are blind
A new thin film technology will let touch-based screens mimic visual displays, helping people who are blind or visually impaired use phones and other devices.
-
FIOCRUZ HIV/AIDS Clinical Trials Unit: advancing HIV prevention and treatment in Brazil
A Brazilian clinical trials unit led by Dr. Beatriz Grinsztejn is testing and speeding up new HIV prevention and treatment strategies to help people living with HIV/AIDS and those at risk.
-
Breeding colony expansion to support HIV/AIDS research with rhesus macaques
A funding opportunity to expand a specialized Rhesus macaque breeding population to support HIV/AIDS research at Tulane’s primate facility.
-
HIV Resilience Observatory in a rhesus macaque colony expansion
A program to build a rhesus macaque breeding colony and use AI-powered monitoring to study why some HIV/AIDS outcomes differ among individuals with similar backgrounds.
-
Indoor-Outdoor Housing Expansion to Support HIV/AIDS-Related Research
A HIV-focused project at a primate research center will use new indoor/outdoor housing and AI-assisted monitoring to study why people with similar backgrounds can have very different HIV outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.